



thor medical

Thor Medical ASA: Share capital increase in relation to Tranche 2 of the Private Placement is registered

15.1.2025 10:31:36 CET | Thor Medical ASA | Changes in the rights attaching to the classes of shares or securities

Oslo, Norway, 15 January 2025: Reference is made to stock exchange announcements by Thor Medical ASA (the "Company") on 12 December 2024 regarding the completion of a private placement of a total of 63,000,000 new shares (the "Offer Shares") in the Company raising a total of NOK 157.5 million (the "Private Placement").

The share capital increase relating to tranche 2 of the Private Placement ("Tranche 1"), consisting of 23,396,380 Offer Shares is now registered with the Norwegian Register of Business Enterprises. The Company's share capital is after the registration NOK 60,777,755, divided into 303,888,775 shares. Each share has a nominal value of NOK 0.20 and represents one vote in the Company's general meeting.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the Securities Trading Act.

CONTACTS

- Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.no

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

Attachments

- [Download announcement as PDF.pdf](#)